FDA Chief Counsel Is Attorney From WLF Case; Porter Leaves After 11 Years
FDA Chief Counsel-designate Daniel Troy is one of the attorneys who successfully challenged the agency's approach to off-label promotion in the WLF suit.
You may also be interested in...
Former FDA attorneys laud her appointment, saying she is highly regarded inside and outside the agency for her intelligence, warmth and expertise on Hatch-Waxman and other key issues.
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said
FDA will continue to protect its regulatory authority by supporting federal preeminence in state product liability suits following the departure of Chief Counsel Dan Troy, Acting Commissioner Lester Crawford said